Pharmaceuticals & Biotech Community
Our community narratives are driven by numbers and valuation.
Pharmaceuticals & Biotech Investing Ideas
Expansion or Overextension? The Risks Behind AFT’s Global Push.
AFT Pharmaceuticals is a New Zealand-based pharmaceutical business with global ambitions. The company has publicly set a goal of achieving NZ$300 million in revenue by the end of 2027—a target repeated in its 2025 annual report, market release, shareholder letter, and chairman’s address.Read more
114
users have viewed this narrative0users have liked this narrative
2users have commented on this narrative
8users have followed this narrative
RO
NZ$2.8
27.5% overvalued intrinsic discount
Robbo's Fair Value
Revenue
7.05% p.a.
Profit Margin
5.75%
Future PE
24.37x
Price in 2030
NZ$3.91
Global Expansion Of High Margin Therapies Will Drive Long Term Healthcare Demand Tailwinds
Catalysts About AFT Pharmaceuticals AFT Pharmaceuticals develops and commercializes specialty and over the counter medicines across Australasia and global markets. What are the underlying business or industry changes driving this perspective?Read more
34
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
NZ$4.2
15.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
14.12% p.a.
Profit Margin
0.078%
Future PE
19.77x
Price in 2028
NZ$0.05
